Pfizer Q4 Revenue Beats Estimates at $17.56B

Pfizer Inc., the New York-based pharmaceutical company, reported fourth-quarter revenue of $17.56 billion on Tuesday, surpassing analyst expectations, though its shares fell nearly 5 percent in early trading amid broader concerns over future growth.

The results showed a quarterly net loss of $1.65 billion, or 29 cents per share, primarily due to one-time items. On an adjusted basis, earnings per share came in at 66 cents, exceeding the average forecast of 57 cents from analysts surveyed by Zacks Investment Research. Revenue also topped estimates of $16.84 billion from four analysts. For the full year, Pfizer's revenue totaled approximately $63 billion, a 2 percent decline from the previous year, while adjusted earnings per share rose 4 percent to $3.22, supported by expanded margins and stable costs.

Oncology products drove much of the performance, with sales growth in treatments like Padcev and Lorbrena helping to offset declines in other areas, such as COVID-19 related revenues. The company highlighted its robust pipeline, planning around 20 pivotal clinical study starts this year to address ongoing challenges including patent expirations and pricing pressures.